Anadys' hepatitis C drug shows promise in midstage trial

12/17/2009 | Reuters

An experimental hepatitis C drug from Anadys Pharmaceuticals helped reduce the virus to an undetectable level in 56% of midstage-trial patients, compared with 20% of the placebo group, after four weeks of treatment. ANA598 was combined with pegylated interferon and ribavirin, a standard therapy.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC